Palmitoylethanolamide (PEA) combined with resistance training may lead to greater improvements in lower body power without interfering with muscle benefits, compared to placebo, says a new study.
Taking the nutraceutical palmitoylethanolamide (PEA) for 60 days has even greater benefits in people with chronic pain than taking PEA for 30 days, adding weight to the potential of the nutraceutical in long-term pain management, concludes a meta-analysis.
Levagen+ is safe and effective for reducing discomfort and duration of migraines in healthy adults, according to a recent study funded by the ingredient's supplier, Gencor Pacific.
A new study suggests that Gencor Pacific’s Levagen+ Palmitoylethanolamide (PEA) ingredient may alleviate symptoms of seasonal allergies as shown by a reduction in histamine and inflammatory markers despite a strong placebo effect.
Palmitoylethanolamide (PEA) reduces sensitivity to pain in the central and peripheral nervous systems and increases pain modulation, says a recent study from Austrian researchers.
Palmitoylethanolamide (PEA) may reduce inflammation and optimise immune responses to infectious conditions such as Covid-19, according to researchers in the USA.
Palmitoylethanolamide (PEA) is a safer and more pervasive therapeutic alternative to cannabidiol, say the authors of the Gencor Pacific-commissioned review, ‘Palmitoylethanolamide: A Potential Alternative to Cannabidiol.’
Eight weeks of supplementation with palmitoylethanolamide, an endocannabinoid-like molecule, may improve sleep measures in healthy adults, according to results of a double-blind, randomized, placebo-controlled study.